CARTICEL

Carticel Adverse Events Reported to the FDA Over Time

How are Carticel adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Carticel, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Carticel is flagged as the suspect drug causing the adverse event.

Most Common Carticel Adverse Events Reported to the FDA

What are the most common Carticel adverse events reported to the FDA?

Arthralgia	33 (9.79%)
Graft Complication	29 (8.61%)
Treatment Failure	21 (6.23%)
Joint Swelling	18 (5.34%)
Loose Body In Joint	10 (2.97%)
Graft Overgrowth	9 (2.67%)
Joint Effusion	9 (2.67%)
Arthropathy	8 (2.37%)
Arthrofibrosis	7 (2.08%)
Failure Of Implant	7 (2.08%)
Joint Range Of Motion Decreased	7 (2.08%)
	Show More
Osteoarthritis	7 (2.08%)
Pulmonary Embolism	7 (2.08%)
Arthritis Infective	6 (1.78%)
Graft Delamination	6 (1.78%)
Joint Adhesion	6 (1.78%)
Chondromalacia	5 (1.48%)
Chondromatosis	5 (1.48%)
Deep Vein Thrombosis	5 (1.48%)
Joint Crepitation	5 (1.48%)
Meniscus Lesion	5 (1.48%)
Synovitis	5 (1.48%)
Joint Lock	4 (1.19%)
Joint Stiffness	4 (1.19%)
Pain	4 (1.19%)
Post Procedural Complication	4 (1.19%)
Post Procedural Infection	4 (1.19%)
Scar	4 (1.19%)
Bone Marrow Oedema	3 (.89%)
Granuloma	3 (.89%)
Pyrexia	3 (.89%)
Swelling	3 (.89%)
Unevaluable Event	3 (.89%)
Wound Dehiscence	3 (.89%)
Arthritis Bacterial	2 (.59%)
Cartilage Injury	2 (.59%)
Cellulitis	2 (.59%)
Device Failure	2 (.59%)
Haematoma	2 (.59%)
Implant Site Reaction	2 (.59%)
Infection	2 (.59%)
Influenza Like Illness	2 (.59%)
Joint Instability	2 (.59%)
Ligament Rupture	2 (.59%)
Osteochondrosis	2 (.59%)
Procedural Complication	2 (.59%)
Rash	2 (.59%)
Staphylococcal Infection	2 (.59%)
Adverse Event	1 (.3%)
Arthroscopy	1 (.3%)
Arthroscopy Abnormal	1 (.3%)
Bone Disorder	1 (.3%)
Breast Cancer	1 (.3%)
Bursitis	1 (.3%)
C-reactive Protein Increased	1 (.3%)
Complications Of Transplant Surgery	1 (.3%)
Device Related Infection	1 (.3%)
Discomfort	1 (.3%)
Disease Progression	1 (.3%)
Drug Ineffective	1 (.3%)
Effusion	1 (.3%)
Erythema	1 (.3%)
Excessive Granulation Tissue	1 (.3%)
Fall	1 (.3%)
Fracture	1 (.3%)
Fracture Treatment	1 (.3%)
Graft Infection	1 (.3%)
Hand Fracture	1 (.3%)
Hepatitis C Antibody Positive	1 (.3%)
Hot Flush	1 (.3%)
Hypotonia	1 (.3%)
Iliotibial Band Syndrome	1 (.3%)
Implant Site Infection	1 (.3%)
Incision Site Complication	1 (.3%)
Inflammation	1 (.3%)
Joint Dislocation	1 (.3%)
Joint Injury	1 (.3%)
Joint Sprain	1 (.3%)
Musculoskeletal Stiffness	1 (.3%)
Nausea	1 (.3%)
Osteonecrosis	1 (.3%)
Patella Fracture	1 (.3%)
Patellofemoral Pain Syndrome	1 (.3%)
Petechiae	1 (.3%)
Post Procedural Haematoma	1 (.3%)
Postoperative Wound Infection	1 (.3%)
Procedural Pain	1 (.3%)
Purulent Discharge	1 (.3%)
Red Blood Cell Sedimentation Rate I...	1 (.3%)
Sinus Tachycardia	1 (.3%)
Skin Infection	1 (.3%)
Tendonitis	1 (.3%)
Transplant Failure	1 (.3%)
Treatment Noncompliance	1 (.3%)
Vomiting	1 (.3%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Carticel, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Carticel is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Carticel

What are the most common Carticel adverse events reported to the FDA?

Joint	126 (37.39%)
Procedural And Device Related Injur...	67 (19.88%)
Therapeutic And Nontherapeutic Effe...	23 (6.82%)
Infections - Pathogen Unspecified	18 (5.34%)
Bone And Joint Injuries	13 (3.86%)
Epidermal And Dermal Conditions	7 (2.08%)
Pulmonary Vascular	7 (2.08%)
Bacterial Infectious	6 (1.78%)
Synovial And Bursal	6 (1.78%)
Embolism And Thrombosis	5 (1.48%)
Skeletal Neoplasms Benign	5 (1.48%)
	Show More
Injuries	4 (1.19%)
Body Temperature Conditions	3 (.89%)
Hematological	3 (.89%)
Tendon, Ligament And Cartilage	3 (.89%)
Administration Site Reactions	2 (.59%)
Bone Disorders	2 (.59%)
Gastrointestinal Signs	2 (.59%)
Musculoskeletal And Soft Tissue Inv...	2 (.59%)
Vascular Hemorrhagic	2 (.59%)
Bone And Joint Therapeutic Procedur...	1 (.3%)
Breast Neoplasms Malignant And Unsp...	1 (.3%)
Cardiac Arrhythmias	1 (.3%)
Hematology Investigations	1 (.3%)
Lifestyle Issues	1 (.3%)
Microbiology And Serology	1 (.3%)
Musculoskeletal And Connective Tiss...	1 (.3%)
Neuromuscular	1 (.3%)
Protein And Chemistry Analyses	1 (.3%)
Skin And Subcutaneous Tissue	1 (.3%)
Skin Vascular Abnormalities	1 (.3%)
Vascular	1 (.3%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Carticel, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Carticel is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.